Evidence map›Paper›PMID 41681992›Full record

ArticleCancers2026

Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy.

Mathew Lin, Jie Jane Chen, Rochelle Bagatell, Sherif G Shaaban, Benjamin J Lerman, Suzanne Shusterman, Myrsini Ioakeim-Ioannidou, Torunn I Yock, Paul J Catalano, Hesham Elhalawani and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Mathew LinDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Jie Jane ChenDepartment of Radiation Oncology, University of California at San Francisco and UCSF Benioff Children's Hospital, San Francisco, CA 94143, USA.ORCID 0000-0002-5380-4825
Rochelle BagatellDepartment of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19146, USA.ORCID 0000-0002-5729-8819
Sherif G ShaabanDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-8443-5655
Benjamin J LermanDepartment of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA 94143, USA.ORCID 0000-0001-9973-6779
Suzanne ShustermanDepartment of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02215, USA.
Myrsini Ioakeim-IoannidouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Torunn I YockDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Paul J CatalanoDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-1105-8852
Hesham ElhalawaniDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Kathryn E DusenberyDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA.
Kieuhoa T VoDepartment of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA 94143, USA.
Mary S HuangDepartment of Pediatric Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Alison M FriedmannDepartment of Pediatric Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Lisa R DillerDepartment of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-4073-5509
Karen J MarcusDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Shannon M MacDonaldDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Stephanie A TerezakisDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California at San Francisco and UCSF Benioff Children's Hospital, San Francisco, CA 94143, USA.ORCID 0000-0002-9841-9357
Christine E Hill-KayserDepartment of Radiation Oncology, University of Pennsylvania and the Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Daphne A Haas-KoganDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Steven G DuBoisDepartment of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-0882-738X
Kevin X LiuDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-2071-5137

Funding

Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6M
NCI NIH HHS K12 CA260225NCI NIH HHS L40 CA264321NCI NIH HHS T32 CA128583NCI NIH HHS T32 CA151022
6 · The paper itself

Abstract

backgroundLimited data inform the outcomes of patients with high-risk neuroblastoma (HR-NBL) who relapse after high-dose chemotherapy, autologous stem cell transplantation (ASCT), and external beam radiotherapy (EBRT).

methodsThis is a multi-institutional retrospective study of 84 patients with HR-NBL diagnosed between 1997-2021 with a first recurrence after definitive upfront treatment, including ≥1 ASCT and EBRT. Site(s) of first relapse were defined with relation to a patient's primary tumor location. Progression-free survival (PFS) and overall survival (OS) outcomes were analyzed using Kaplan-Meier curves and log-rank tests. Cox proportional hazard models were used for univariate and multivariable analyses.

resultsTwenty-four patients had local recurrences with or without distant relapses (LR) and 60 had distant relapses only. The LR cohort had higher rates of

conclusionsPatients with relapsed HR-NBL have poor outcomes with median OS < 2 years. Time to relapse was a significant predictor of OS.

Indexed as

palliative radiotherapyphoton radiotherapyproton radiotherapysurgerytime to relapse

Identifiers

PMID41681992
PMCPMC12897123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.